home

Building its cardio drug portfolio, Amgen bags Dezima in $1.55B deal

TrendPharmacodia.com2015-09-16 00:00 Read   369

Amgen is acquiring Dutch biotech Dezima for $300 million up front and $1.25 billion in milestones, tackling another potential blockbuster franchise that has spurred billions of dollars in often frustrating research programs.

XenoPort plunges as investors sour fast on 'positive' psoriasis data

TrendPharmacodia.com2015-09-15 00:00 Read   299

Shares of Santa Clara, CA-based XenoPort were crushed today after the biotech touted what it called positive preliminary efficacy results from a midstage study of its oral psoriasis drug. While the biotech claimed that its drug is ready for Phase III, XenoPort faces a crowded set of late-stage rivals with a drug that posted some troubling side effects. And investors swiftly turned from upbeat to skeptical this morning as they had a chance to ponder the results, sending shares down 23% by midmorning.

Collegium waits for FDA approval with its abuse-deterrent painkiller

TrendPharmacodia.com2015-09-14 00:00 Read   399

Collegium Pharmaceuticals' hard-to-abuse opioid treatment won unanimous backing from a panel of FDA advisers, clearing the path to a likely approval next month.

Gene therapy player Dimension catches the biotech IPO wave, files $115M offering

R&DPharmacodia.com2015-09-14 00:00 Read   277

Dimension Therapeutics is preparing to execute the next carefully planned step in its evolution, filing for a $115 million IPO close to 5 months after its crossover round landed.